Resistance to endocrine therapy in breast cancer: molecular mechanisms and future goals
Open accessThe DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The majority of breast cancers (BCs) are characterized by the expression of estrogen receptor alpha (ERα+). ERα acts as ligand-dependent transcription factor for genes associated with cell survival, proliferation, and tumor growth. Thus, blocking the estrogen agonist effect on ERα is the main strategy in the treatment of ERα+ BCs. However, despite the development of targeted anti-estrogen therapies for ER+ BC, around 30-50% of early breast cancer patients will relapse. Acquired resistance to endocrine therapy is a great challenge in ER+ BC patient treatment. DISCUSSION: Anti-estrogen resistance is a consequence of molecular changes, which allow for tumor growth irrespective of estrogen presence. Those changes may be associated with ERα modifications either at the genetic, regulatory or protein level. Additionally, the activation of alternate growth pathways and/or cell survival mechanisms can lead to estrogen-independence and endocrine resistance. CONCLUSION: This comprehensive review summarizes molecular mechanisms associated with resistance to anti-estrogen therapy, focusing on genetic alterations, stress responses, cell survival mechanisms, and cell reprogramming.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Core Transcriptional Regulatory Circuitry in Human Embryonic Stem Cells
Boyer, L. A., Lee, T. I., Cole, M. F., Johnstone, S. E., Levine, S. S., Zucker, J. P., Guenther, M. G., Kumar, R. M., Murray, H. L., Jenner, R. G., et al. (2005) · Cell · doi:10.1016/j.cell.2005.08.020 · Cited by 4,505
Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J.-A. (1997) · Endocrinology · doi:10.1210/endo.138.3.4979 · Cited by 4,442
Regulation mechanisms and signaling pathways of autophagy
He, C., & Klionsky, D. J. (2009) · Annual Review of Genetics · doi:10.1146/annurev-genet-102808-114910 · Cited by 3,609
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Ben-Porath, I., Thomson, M. W., Carey, V. J., Ge, R., Bell, G. W., Regev, A., & Weinberg, R. A. (2008) · Nature Genetics · doi:10.1038/ng.127 · Cited by 2,523
Nutrient-dependent mTORC1 Association with the ULK1–Atg13–FIP200 Complex Required for Autophagy
Hosokawa, N., Hara, T., Kaizuka, T., Kishi, C., Takamura, A., Miura, Y., Iemura, S.-I., Natsume, T., Takehana, K., Yamada, N., et al. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-12-1248 · Cited by 2,076
Mammalian autophagy: core molecular machinery and signaling regulation
Yang, Z., & Klionsky, D. J. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2009.11.014 · Cited by 1,956
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Mechanisms of Endocrine Resistance in Breast Cancer
Osborne, C. K., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,166
Polakis, P. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008052 · Cited by 847
Estrogen synthesis and signaling pathways during aging: from periphery to brain
Cui, J., Shen, Y., & Li, R. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.12.007 · Cited by 779
Nuclear reprogramming to a pluripotent state by three approaches
Yamanaka, S., & Blau, H. M. (2010) · Nature · doi:10.1038/nature09229 · Cited by 776
MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1
Miller, T. E., Ghoshal, K., Ramaswamy, B., Roy, S., Datta, J., Shapiro, C. L., Jacob, S., & Majumder, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804612200 · Cited by 749
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722
Estrogen receptors alpha (ERα) and beta (ERβ): Subtype-selective ligands and clinical potential
Paterni, I., Granchi, C., Katzenellenbogen, J. A., & Minutolo, F. (2014) · Steroids · doi:10.1016/j.steroids.2014.06.012 · Cited by 721
ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M., & Schiff, R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.117 · Cited by 704
Li, S., Shen, D., Shao, J., Crowder, R., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 626
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
Paplomata, E., & O’Regan, R. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014530023 · Cited by 593
Arpino, G., Wiechmann, L., Osborne, C. K., & Schiff, R. (2008) · Endocrine Reviews · doi:10.1210/er.2006-0045 · Cited by 549
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay
Wallden, B., Storhoff, J., Nielsen, T., Dowidar, N., Schaper, C., Ferree, S., Liu, S., Leung, S., Geiss, G., Snider, J., et al. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0129-6 · Cited by 542
Bursch, W., Ellinger, A., Kienzl, H., Török, L., Pandey, S., Sikorska, M., Walker, R., & Hermann, R. S. (1996) · Carcinogenesis · doi:10.1093/carcin/17.8.1595 · Cited by 516
Dedifferentiation and reprogramming: origins of cancer stem cells
Friedmann‐Morvinski, D., & Verma, I. M. (2014) · EMBO reports · doi:10.1002/embr.201338254 · Cited by 495
Luminal breast cancer: from biology to treatment
Ignatiadis, M., & Sotiriou, C. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.124 · Cited by 469
The structure of the nuclear hormone receptors
Kumar, R., & Thompson, E. B. (1999) · Steroids · doi:10.1016/s0039-128x(99)00014-8 · Cited by 435
Flouriot, G. (2000) · The EMBO Journal · doi:10.1093/emboj/19.17.4688 · Cited by 425
Merenbakh-Lamin, K., Ben-Baruch, N., Yeheskel, A., Dvir, A., Soussan-Gutman, L., Jeselsohn, R., Yelensky, R., Brown, M., Miller, V. A., Sarid, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1197 · Cited by 393
Wang, Z., Zhang, X., Shen, P., Loggie, B. W., Chang, Y., & Deuel, T. F. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.226 · Cited by 392
De Mattos-Arruda, L., Weigelt, B., Cortes, J., Won, H. H., Ng, C. K. Y., Nuciforo, P., Bidard, F.-C., Aura, C., Saura, C., Peg, V., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu239 · Cited by 386
Wang, Z., Zhang, X., Shen, P., Loggie, B. W., Chang, Y., & Deuel, T. F. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603339103 · Cited by 380
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer
Holst, F., Stahl, P. R., Ruiz, C., Hellwinkel, O., Jehan, Z., Wendland, M., Lebeau, A., Terracciano, L., Al-Kuraya, K., Jänicke, F., et al. (2007) · Nature Genetics · doi:10.1038/ng2006 · Cited by 375
Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells
Wei, Y., Lai, X., Yu, S., Chen, S., Ma, Y., Zhang, Y., Li, H., Zhu, X., Yao, L., & Zhang, J. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3037-0 · Cited by 354
Rao, X., Di Leva, G., Li, M., Fang, F., Devlin, C., Hartman-Frey, C., Burow, M. E., Ivan, M., Croce, C. M., & Nephew, K. P. (2011) · Oncogene · doi:10.1038/onc.2010.487 · Cited by 342
Zhang, Q., Borg, Å., Wolf, D. M., Oesterreich, S., & Fuqua, S. A. W. (1997) · PubMed · Cited by 337
Nielsen, T., Wallden, B., Schaper, C., Ferree, S., Liu, S., Gao, D., Barry, G., Dowidar, N., Maysuria, M., & Storhoff, J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-177 · Cited by 311
Biology and Management of Patients With Triple-Negative Breast Cancer
Sharma, P. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0067 · Cited by 294
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
Zhang, X. H.-F., Giuliano, M., Trivedi, M. V., Schiff, R., & Osborne, C. K. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0838 · Cited by 264
Weis, K. E. (1996) · Molecular Endocrinology · doi:10.1210/me.10.11.1388 · Cited by 236
Lambertini, M., Ceppi, M., Poggio, F., Peccatori, F. A., Azim, H. A., Ugolini, D., Pronzato, P., Loibl, S., Moore, H. C. F., Partridge, A. H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv374 · Cited by 228
Chloroquine Inhibits Autophagy to Potentiate Antiestrogen Responsiveness in ER+ Breast Cancer
Cook, K. L., Wärri, A., Soto-Pantoja, D. R., Clarke, P. A., Cruz, M. I., Zwart, A., & Clarke, R. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3227 · Cited by 226
Clarke, R., Cook, K. L., Hu, R., Facey, C. O. B., Tavassoly, I., Schwartz, J. L., Baumann, W. T., Tyson, J. J., Xuan, J., Wang, Y., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3213 · Cited by 217
Structural underpinnings of oestrogen receptor mutations in endocrine therapy resistance
Katzenellenbogen, J. A., Mayne, C. G., Katzenellenbogen, B. S., Greene, G. L., & Chandarlapaty, S. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0001-z · Cited by 216
Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer
Anbalagan, M., & Rowan, B. G. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.01.016 · Cited by 194
Molecular Profiling for Breast Cancer: A Comprehensive Review
Kittaneh, M., Montero, A. J., & Glück, S. (2013) · Biomarkers in Cancer · doi:10.4137/bic.s9455 · Cited by 190
Samaddar, J. S., Gaddy, V. T., Duplantier, J., Thandavan, S. P., Shah, M., Smith, M. J., Browning, D., Rawson, J., Smith, S. B., Barrett, J. T., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0447 · Cited by 189
Estrogen receptor beta in breast cancer
Haldosén, L.-A., Zhao, C., & Dahlman-Wright, K. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.005 · Cited by 189
Breast cancer stem cells, EMT and therapeutic targets
Kotiyal, S., & Bhattacharya, S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.09.069 · Cited by 187
PI3K/Akt/mTOR inhibitors in breast cancer
Joycelyn, Jx, Lee, Kiley, Loh, K. W.-J., Yoon-Sim, & Yap (2015) · 癌症生物学与医学:英文版 · Cited by 185
NF-κB, stem cells and breast cancer: the links get stronger
Shostak, K., & Chariot, A. (2011) · Breast Cancer Research · doi:10.1186/bcr2886 · Cited by 180
Veeraraghavan, J., Tan, Y., Cao, X.-X., Kim, J. A., Wang, X., Chamness, G. C., Maiti, S. N., Cooper, L. J. N., Edwards, D. P., Contreras, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms5577 · Cited by 176
Autophagy and endocrine resistance in breast cancer
Cook, K. L., Shajahan, A. N., & Clarke, R. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.111 · Cited by 170
Cook, K. L., Shajahan, A. N., Wärri, A., Jin, L., Hilakivi-Clarke, L. A., & Clarke, R. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0269 · Cited by 161
Wang, Q., Jiang, J., Ying, G., Xie, X.-Q., Zhang, X., Xu, W., Zhang, X., Song, E., Bu, H., Ping, Y., et al. (2018) · Cell Research · doi:10.1038/cr.2018.15 · Cited by 158
PI3K/Akt/mTOR inhibitors in breast cancer.
Lee, J. J. X., Loh, K. W.-J., & Yap, Y. S. (2015) · PubMed · doi:10.7497/j.issn.2095-3941.2015.0089 · Cited by 142
Lessons learnt from structural studies of the oestrogen receptor
Pike, A. C. W. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2005.09.002 · Cited by 140
Nelson, A. W., Groen, A. J., Miller, J. L., Warren, A. Y., Holmes, K. A., Tarulli, G. A., Tilley, W. D., Katzenellenbogen, B. S., Hawse, J. R., Gnanapragasam, V. J., et al. (2016) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2016.11.016 · Cited by 128
Autophagy facilitates the progression of ERα-positive breast cancer cells to antiestrogen resistance
Schoenlein, P. V., Periyasamy-Thandavan, S., Samaddar, J. S., Jackson, W. H., & Barrett, J. T. (2009) · Autophagy · doi:10.4161/auto.5.3.7784 · Cited by 126
Mammary Development and Breast Cancer: A Wnt Perspective
Yu, Q. C., Verheyen, E. M., & Zeng, Y. A. (2016) · Cancers · doi:10.3390/cancers8070065 · Cited by 126
Andruska, N. D., Zheng, X., Yang, X., Helferich, W. G., & Shapiro, D. J. (2014) · Oncogene · doi:10.1038/onc.2014.292 · Cited by 122
Zhao, Y., Deng, C., Lu, W., Xiao, J., Ma, D., Guo, M., Recker, R. R., Gatalica, Z., Wang, Z., & Xiao, G. G. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00225 · Cited by 117
Cui, J., Yang, Y., Li, H., Leng, Y.-J., Qian, K., Huang, Q., Zhang, C., Zhao, L., Chen, J., Sun, T., et al. (2014) · Oncogene · doi:10.1038/onc.2014.430 · Cited by 116
Itoh, M., Iwamoto, T., Matsuoka, J., Nogami, T., Motoki, T., Shien, T., Taira, N., Niikura, N., Hayashi, N., Shoichiro, O., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2763-z · Cited by 113
Cell cycle control of pituitary development and disease
Quereda, V., & Malumbres, M. (2008) · Journal of Molecular Endocrinology · doi:10.1677/jme-08-0146 · Cited by 111
Bora-Singhal, N., Perumal, D., Nguyen, J., & Chellappan, S. (2015) · Neoplasia · doi:10.1016/j.neo.2015.07.001 · Cited by 110
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer
Lei, J. T., Shao, J., Zhang, J., Iglesia, M. D., Chan, D. W., Cao, J., Anurag, M., Singh, P., He, X., Kosaka, Y., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.009 · Cited by 109
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
Hartmaier, R. J., Trabucco, S. E., Priedigkeit, N., Chung, J., Parachoniak, C. A., Borre, P. V., Morley, S., Rosenzweig, M. R., Gay, L. M., Goldberg, M. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy025 · Cited by 109
MiRNA-155 mediates TAM resistance by modulating SOCS6-STAT3 signalling pathway in breast cancer.
Shen, R., Wang, Y., Wang, C., Yin, M., Liu, H., Chen, J., Han, J., & Wang, W.-B. (2015) · Europe PMC (PubMed Central) · Cited by 108
COROMINAS-FAJA, B., CUFÍ, S., Oliveras-Ferraros, C., CUYÀS, E., López-Bonet, E., LUPU, R., ALARCÓN, T., Vellon, L., MANUEL IGLESIAS, J., LEIS, O., et al. (2013) · Cell Cycle · doi:10.4161/cc.26173 · Cited by 105
Predicting endocrine therapy responsiveness in breast cancer.
Ma, C. X., Sanchez, C. G., & Ellis, M. J. (2009) · PubMed · Cited by 104
Cook, K. L., Clarke, P. A. G., Parmar, J. H., Hu, R., Schwartz‐Roberts, J. L., Abu-Asab, M. S., Wärri, A. M., Baumann, W. T., & Clarke, R. C. (2014) · The FASEB Journal · doi:10.1096/fj.13-247353 · Cited by 98
ESR1 gene amplification in breast cancer: a common phenomenon?
Reis-Filho, J. S., Drury, S., Lambros, M. B. K., Marchiò, C., Johnson, N., Natrajan, R., Salter, J., Levey, P. M., Fletcher, O., Peto, J., et al. (2008) · Nature Genetics · doi:10.1038/ng0708-809b · Cited by 85
A Good Drug Made Better: The Fulvestrant Dose-Response Story
Robertson, J. F. R., Lindemann, J. P. O., Garnett, S., Anderson, E., Nicholson, R. I., Kuter, I., & Gee, J. M. W. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.06.005 · Cited by 79
Tomita, S., Zhang, Z., Nakano, M., Ibusuki, M., Kawazoe, T., Yamamoto, Y., & Iwase, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01145.x · Cited by 78
Hippo pathway in mammary gland development and breast cancer
Shi, P., Feng, J. C., & Chen, C. (2015) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmu114 · Cited by 74
Pavlin, M., Spinello, A., Pennati, M., Zaffaroni, N., Gobbi, S., Bisi, A., Colombo, G., & Magistrato, A. (2018) · Scientific Reports · doi:10.1038/s41598-017-17364-4 · Cited by 71
Mou, W., Xu, Y., Ye, Y., Chen, S., Li, X., Gong, K., Liu, Y., Chen, Y., Li, X., Tian, Y., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.004 · Cited by 70
ESR1 gene amplification in breast cancer: a common phenomenon?
Brown, L. A., Hoog, J., Chin, S., et al. (2008) · Nature Genetics · doi:10.1038/ng0708-806 · Cited by 66
Reese, J. M., Bruinsma, E. S., Nelson, A. W., Chernukhin, I. V., Carroll, J. S., Li, Y., Subramaniam, M., Suman, V. J., Negron, V. C., Monroe, D. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1807751115 · Cited by 65
Pelekanou, V., Notas, G., Kampa, M., Tsentelierou, E., Radojicic, J., Leclercq, G., Castanas, E., & Stathopoulos, E. N. (2011) · Steroids · doi:10.1016/j.steroids.2011.12.016 · Cited by 60
Nielsen, K. V., Ejlertsen, B., Müller, S., Möller, S., Rasmussen, B., Balslev, E., Lænkholm, A., Christiansen, P., & Mouridsen, H. T. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-0984-y · Cited by 60
Campos-Parra, A. D., Cuamani-Mitznahuatl, G., Pedroza‐Torres, A., Romo, R., Porras-Reyes, F. I., López–Urrutia, E., & Pérez‐Plasencia, C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061182 · Cited by 56
Anticipatory UPR Activation: A Protective Pathway and Target in Cancer
Shapiro, D. J., Livezey, M. R., Yu, L., Zheng, X., & Andruska, N. D. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.06.002 · Cited by 56
Zhang, K., Hong, R., Xu, F., Xia, W., Lee, K., Qin, G., Zheng, Q., Lu, Q., Shi, Y. X., Yuan, Z. Y., et al. (2018) · Cancer Management and Research · doi:10.2147/cmar.s173193 · Cited by 52
Duan, L., Motchoulski, N., Danzer, B., Davidovich, I., Shariat‐Madar, Z., & Levenson, V. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.143271 · Cited by 46
Roop, R. P., & Ma, C. X. (2012) · Future Oncology · doi:10.2217/fon.12.8 · Cited by 44
Flemban, A. F., & Qualtrough, D. (2015) · Cancers · doi:10.3390/cancers7030866 · Cited by 44
Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers
Clarke, R. C., & Cook, K. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00140 · Cited by 43
The Adjuvant Treatment of HER2-Positive Breast Cancer
Jelovac, D., & Wolff, A. C. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-012-0186-4 · Cited by 43
Prognostic implications of receptor discordance between primary and recurrent breast cancer
Matsumoto, A., Jinno, H., Murata, T., Seki, T., Takahashi, M., Hayashida, T., Kameyama, K., & Kitagawa, Y. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0759-2 · Cited by 39
Stendahl, M., Nilsson, S., Wigerup, C., Jirström, K., Jönsson, P., Stål, O., & Landberg, G. (2010) · International Journal of Cancer · doi:10.1002/ijc.25297 · Cited by 33
Leung, E. Y., Askarian-Amiri, M., Sarkar, D., Ferraro‐Peyret, C., Joseph, W. R., Finlay, G. J., & Baguley, B. C. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00184 · Cited by 32
Interplay Between Genetic and Epigenetic Changes in Breast Cancer Subtypes
Dumitrescu, R. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8751-1_2 · Cited by 30
Polo, M. L., Riggio, M., May, M., Rodriguez, M. J., Perrone, M. C., Stallings‐Mann, M. L., Kaen, D. L., Frost, M. H., Goetz, M. P., Boughey, J. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4203 · Cited by 28
Moelans, C. B., Holst, F., Hellwinkel, O., Simon, R., & van Diest, P. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0084189 · Cited by 19
Skafar, D. F. (2007) · Cell Biochemistry and Biophysics · doi:10.1385/cbb:33:1:53 · Cited by 12
Cited by
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Tian, Q., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 347
Role of estrogen receptors in health and disease
Chen, P., Li, B., & Ou-Yang, L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.839005 · Cited by 339
Metadata
- Authors
- Szostakowska, M., Trębińska-Stryjewska, A., Grzybowska, E. A., & Fabisiewicz, A.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2018-11-01
- Volume
- 173
- Issue
- 3
- Pages
- 489-497
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2899181045
- Cited by
- 161
- References
- 96
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.